Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I perioperative peptide vaccine combination immunotherapy for resectable hepatocellular carcinoma
jRCTs061180033Phase 1Completed
- Sponsor
- CYTLIMIC
- Start
- Jan 2018
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HSP70-derived peptide, GPC3-derived peptide, eftilagimod alpha and poly iclc in hepatocellular carcinoma (HCC), sponsored by CYTLIMIC. Primary endpoint: Safety. Started Jan 2018; status: completed.
02
Drugs
HSP70-derived peptideGPC3-derived peptideeftilagimod alphapoly iclc
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs061180033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180033.